FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer

被引：0
|
作者：
Cuilan Sun
Weiwei Gao
Jiatao Liu
Hao Cheng
Jiqing Hao
机构：
[1] The First Affiliated Hospital of Anhui Medical University,Department of Oncology
[2] the First Affiliated Hospital of Anhui Medical University,Department of Pharmacy
来源：
Respiratory Research | / 21卷
关键词：
Fibrinogen-like-protein 1; Epidermal growth factor receptor; Non-small cell lung cancer; Gefitinib resistance; Apoptosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] BRMS1 Regulates Apoptosis in Non-small Cell Lung Cancer Cells
    You, Jijun
    He, Xuejun
    Ding, Haibing
    Zhang, Tingrong
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2015, 71 (01) : 465 - 472
  • [22] Gefitinib therapy for non-small cell lung cancer
    Birnbaum A.
    Ready N.
    Current Treatment Options in Oncology, 2005, 6 (1) : 75 - 81
  • [23] BRMS1 Regulates Apoptosis in Non-small Cell Lung Cancer Cells
    Jijun You
    Xuejun He
    Haibing Ding
    Tingrong Zhang
    Cell Biochemistry and Biophysics, 2015, 71 : 465 - 472
  • [24] Gefitinib for advanced non-small cell lung cancer
    Sim, Esther H. A.
    Yang, Ian A.
    Wood-Baker, Richard
    Bowman, Rayleen V.
    Fong, Kwun M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (01):
  • [25] Gefitinib in advanced non-small cell lung cancer
    Sharma, R
    Boyer, M
    Clarke, S
    Millward, M
    INTERNAL MEDICINE JOURNAL, 2005, 35 (02) : 77 - 82
  • [26] EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION AND ACQUIRED RESISTANCE TO GEFITINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Li, Chenglin
    Zhou, Fengfeng
    ACTA MEDICA MEDITERRANEA, 2020, 36 (03): : 1489 - 1493
  • [27] Degradation of AXL overcome acquired cross-resistance to gefitinib and osimertinib in non-small cell lung cancer cells
    Kim, Donghwa
    Bach, Duc-Hiep
    Fan, Yan-hua
    Luu, Thi-Thu-Trang
    Hong, Ji-Young
    Park, Hyen-Joo
    Lee, Sang Kook
    CANCER RESEARCH, 2019, 79 (13)
  • [28] Role of ERK reactivation mediated by Src in acquired resistance to gefitinib in non-small cell lung cancer with EGFR mutation
    Ochi, Nobuaki
    Takigawa, Nagio
    Ohashi, Kadoaki
    Takeda, Hiromasa
    Fujii, Masanori
    Kubo, Toshio
    Ichihara, Eiki
    Hotta, Katsuyuki
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    CANCER RESEARCH, 2011, 71
  • [29] Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment
    Kim, Hye-Ryoun
    Lee, Jae Chol
    Kim, Young-Chul
    Kim, Kyu-Sik
    Oh, In-Jae
    Lee, Sung Yong
    Jang, Tae Won
    Lee, Min Ki
    Shin, Kyeong-Cheol
    Lee, Gwan Ho
    Ryu, Jeong-Seon
    Jang, Seung Hoon
    Son, Ji Woong
    Lee, Jeong Eun
    Kim, Sun Young
    Kim, Hee Joung
    Lee, Kye Young
    LUNG CANCER, 2014, 83 (02) : 252 - 258
  • [30] Overexpression of Cathepsin L is associated with gefitinib resistance in non-small cell lung cancer
    Cui, F.
    Wang, W.
    Wu, D.
    He, X.
    Wu, J.
    Wang, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (07): : 722 - 727
12345